Pancreatic cancer: survival, errors and evidence

Gudjonsson, Birgir

doi:10.1097/meg.0b013e328323aab7

Cited by 31 publications

(22 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An occasional resected patient may certainly survive 5 years but will then most likely be reported over and over in the literature (Gudjonsson 2009). …”

Section: Operative Findingsmentioning

confidence: 99%

Pancreatic Cancer - Clinical Course and Survival

Gudjonsson¹

2012

Pancreatic Cancer - Clinical Management

Self Cite

View full text Add to dashboard Cite

“…An occasional resected patient may certainly survive 5 years but will then most likely be reported over and over in the literature (Gudjonsson 2009). …”

Section: Operative Findingsmentioning

confidence: 99%

Pancreatic Cancer - Clinical Course and Survival

Gudjonsson¹

2012

Pancreatic Cancer - Clinical Management

Self Cite

View full text Add to dashboard Cite

“…The vast majority of patients with pancreatic cancer are not diagnosed until their cancer has metastasized, and so surgical treatment is the only curative treatment. However, due to this late diagnosis the majority of patients present in an advanced stage, and only a minority (10-20%) of these patients are amenable to surgical intervention (4,5). Even when diagnosed early enough to be potentially resectable, the prognosis of invasive pancreatic cancer is poor.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA profiles during galectin‑9‑induced apoptosis of pancreatic cancer cells

et al. 2017

View full text Add to dashboard Cite

Abstract. Pancreatic cancer is the eighth-leading cause of cancer-associated mortality in males and the ninth-leading cause in females worldwide. Even when diagnosed early enough to be potentially resectable, the prognosis of invasive pancreatic cancer is poor. Galectin-9 (Gal-9) is a tandem-repeat type galectin that has recently been demonstrated to possess an anti-proliferative effect on cancer cells. Therefore, the present study evaluated the effects of Gal-9 on the proliferation of human pancreatic cancer cells and examined the microRNAs that are associated with the antitumor effects of Gal-9. Gal-9 suppressed the proliferation of multiple pancreatic cancer cell lines. In addition, Gal-9 treatment increased the levels of caspase-cleaved keratin 18 and the expression of cytochrome c in pancreatic cancer cell lines. This data suggests that Gal-9 induces intrinsic apoptosis in pancreatic cancer cell lines through the caspase-dependent and caspase-independent pathways. In addition, Gal-9 reduced the expression levels of phosphorylated epidermal growth factor receptor and numerous receptor tyrosine kinases (RTKs). In conclusion, Gal-9 may suppress the growth of human pancreatic cancer cells in vitro. These findings suggest that Gal-9 may be a new therapeutic agent for the treatment of pancreatic cancer.

show abstract

“…Due to the aggressive nature and disadvantageous prognosis, patients suffering from pancreatic cancer still show 5-year survival of as little as 1% [1] and survival time of a few months only [2]. Both incidence and mortality have barely changed over the past 20 years, with diagnosis still happening late [3].…”

Section: Introductionmentioning

confidence: 99%

Lysyloxidase-4 is a selectively expressed candidate diagnostic antigen in pancreatic cancer

Kiel¹,

Quabius²,

Ambrosch³

et al. 2017

Med Clin Arch

View full text Add to dashboard Cite

Lysyl oxidases (LOX) catalyze collagen and elastin cross-linking but also facilitate tumor genesis and progression. In this study, we used a monoclonal antibody directed against LOX like-4 (LOXL-4) on pancreatic cancer tissue specimens of 103 patients to examine its diagnostic and prognostic value. In 88.3% of pancreatic cancer specimens, LOXL-4 was detectable, whereas it could not be shown in benign oral mucosa control specimens. The level of LOXL-4 expression strongly correlated with T stage and lymph node status but not with occurrence of distant metastases or overall patient survival. These results substantially strengthen the existing immunohistochemical studies on LOXL-4 in different malignomas and clearly suggest a diagnostic value of LOXL-4 in pancreatic carcinoma and do contribute to the ongoing discussion about to what extent LOXL-4 might be a suitable marker in cancer diagnosis and progression.

show abstract

Pancreatic cancer: survival, errors and evidence

Abstract: After adjusting for calculations and duplications, the total number of 5-year survivors can hardly be more than 700-800.

Cited by 31 publications

References 42 publications

Pancreatic Cancer - Clinical Course and Survival

Pancreatic Cancer - Clinical Course and Survival

MicroRNA profiles during galectin‑9‑induced apoptosis of pancreatic cancer cells

Lysyloxidase-4 is a selectively expressed candidate diagnostic antigen in pancreatic cancer

Contact Info

Product

Resources

About